Menu Menu


GSK Financials       Clear


GSK        0001131399    
Filing Date Form Type Description Document
2026-02-25 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-25 6-K GSK ENTERS AGREEMENT TO ACQUIRE 35PHARMA View Document
2026-02-25 6-K TRANSACTION IN OWN SHARES View Document
2026-02-24 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-24 6-K TRANSACTION IN OWN SHARES View Document
2026-02-24 SC TO-T/A SC TO-T/A View Document
2026-02-23 6-K TRANSACTION IN OWN SHARES View Document
2026-02-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-20 6-K TRANSACTION IN OWN SHARES View Document
2026-02-19 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-19 6-K TRANSACTION IN OWN SHARES View Document
2026-02-18 6-K TRANSACTION IN OWN SHARES View Document
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-17 6-K GSK - FOURTH TRANCHE OF SHARE BUYBACK PROGRAMME View Document
2026-02-17 6-K EXDENSUR APPROVED BY THE EUROPEAN COMMISSION View Document
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-12 13F-HR View Document
2026-02-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-10 6-K CHINA CDE ACCEPTS AREXVY ADULTS 60+ APPLICATION View Document
2026-02-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-06 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-06 6-K NUCALA COPD APPROVED BY THE EUROPEAN COMMISSION View Document
2026-02-05 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-04 6-K FINAL RESULTS View Document
2026-02-02 6-K TOTAL VOTING RIGHTS View Document
2026-02-02 SC TO-T SC TO-T View Document
2026-01-26 6-K EUROPEAN COMMISSION APPROVES AREXVY FOR ADULTS 18+ View Document
2026-01-20 SC TO-C SC TO-C View Document
2026-01-20 SC TO-C SC TO-C View Document
2026-01-20 6-K GSK TO ACQUIRE RAPT THERAPEUTICS View Document
2026-01-20 6-K AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDING View Document
2026-01-16 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-01-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-01-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-01-07 6-K EC APPROVAL OF SHINGRIX PFS View Document
2026-01-07 6-K POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSEN View Document
2026-01-06 6-K EXDENSUR APPROVED IN JAPAN View Document
2026-01-05 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-01-05 6-K TOTAL VOTING RIGHTS View Document
2026-01-05 6-K NUCALA FOR ADULTS WITH COPD APPROVED IN CHINA View Document
2025-12-23 6-K GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN US View Document
2025-12-22 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-12-22 6-K TRANSACTION IN OWN SHARES View Document
2025-12-19 6-K TRANSACTION IN OWN SHARES View Document
2025-12-18 6-K TRANSACTION IN OWN SHARES View Document
2025-12-17 6-K EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA View Document
2025-12-17 6-K TRANSACTION IN OWN SHARES View Document
2025-12-16 6-K EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVAL View Document
2025-12-16 6-K TRANSACTION IN OWN SHARES View Document
2025-12-15 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP View Document
2025-12-15 6-K TRANSACTION IN OWN SHARES View Document
2025-12-12 6-K DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINION View Document
2025-12-12 6-K NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPD View Document
2025-12-12 6-K POSITIVE CHMP OPINION ON AREXVY FOR ALL ADULTS 18+ View Document
2025-12-12 6-K TRANSACTION IN OWN SHARES View Document
2025-12-11 6-K BLUJEPA APPROVED IN US FOR GONORRHOEA INDICATION View Document
2025-12-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-12-11 6-K BLOCK LISTING APPLICATION View Document
2025-12-11 6-K TRANSACTION IN OWN SHARES View Document
2025-12-10 6-K TRANSACTION IN OWN SHARES View Document
2025-12-10 6-K GSK'227 US FDA ORPHAN DRUG DESIGNATION IN SCLC View Document
2025-12-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-12-09 6-K TRANSACTION IN OWN SHARES View Document
2025-12-08 6-K TRANSACTION IN OWN SHARES View Document
2025-12-05 SCHEDULE 13D/A View Document
2025-12-05 6-K TRANSACTION IN OWN SHARES View Document
2025-12-04 6-K TRANSACTION IN OWN SHARES View Document
2025-12-03 6-K TRANSACTION IN OWN SHARES View Document
2025-12-02 6-K TRANSACTION IN OWN SHARES View Document
2025-12-01 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-12-01 6-K TOTAL VOTING RIGHTS View Document
2025-12-01 6-K TRANSACTION IN OWN SHARES View Document
2025-11-28 6-K TRANSACTION IN OWN SHARES View Document
2025-11-28 6-K TRANSACTION IN OWN SHARES View Document
2025-11-26 6-K TRANSACTION IN OWN SHARES View Document
2025-11-25 6-K TRANSACTION IN OWN SHARES View Document
2025-11-24 6-K TRANSACTION IN OWN SHARES View Document
2025-11-21 6-K INITIATION OF LITIGATION AGAINST ANAPTYSBIO INC View Document
2025-11-21 6-K TRANSACTION IN OWN SHARES View Document
2025-11-20 6-K TRANSACTION IN OWN SHARES View Document
2025-11-19 6-K TRANSFER OF TREASURY SHARES View Document
2025-11-19 6-K TRANSACTION IN OWN SHARES View Document
2025-11-18 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-11-18 6-K TRANSACTION IN OWN SHARES View Document
2025-11-17 6-K TRANSACTION IN OWN SHARES View Document
2025-11-14 6-K TRANSACTION IN OWN SHARES View Document
2025-11-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-11-13 6-K TRANSACTION IN OWN SHARES View Document
2025-11-12 6-K BLOCK LISTING INTERIM REVIEW View Document
2025-11-12 6-K TRANSACTION IN OWN SHARES View Document
2025-11-12 6-K TRANSACTION IN OWN SHARES View Document
2025-11-10 6-K GSK PUBLISHES PROVISIONAL DIVIDEND DATES View Document
2025-11-10 6-K TRANSACTION IN OWN SHARES View Document
2025-11-07 6-K TRANSACTION IN OWN SHARES View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299